RAREのROE（自己資本利益率）は？

UltragenyxのROEは258.21%です。

RAREの配当利回りは？

Ultragenyxの配当利回りは0.00%です。

RAREの品質スコア（Quality Score）は？

当社のAIはRAREの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。

RAREは今が買い時ですか？

当社AIのタイミングスコアは100点中56点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。

RAREはどのセクターに属しますか？

UltragenyxはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）

RARE (NASDAQ) 株価分析 | ULTRAGENYX

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

RARE AI Analysis Summary

Our AI summary for RARE: Ultragenyx (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of 258.21%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 56/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

RARE

Ultragenyx

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 25.02

0.11 (0.44%) Day Change

Watchlist Portfolio Compare Chart

-0.31

D/E

258.2%

ROE

-47.0%

ROA

0.00%

Div Yield

ULTRAGENYX
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 25.02 Price 0.11 (0.44%) Day Change	NEWS SCORE: N/A

RARE, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そしてテクニカルスコアは ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROAが低い
ROEの伸びが低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Deepscope 分析

47%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	25.02
PBV / Sector	-10.71 / 44,219.29
Earning Per Share	-6.21

PE / Sector	N/A / 19.28
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	54.82 M
Average 1W Daily Value	49.92 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

ポイントになる統計

52%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-91.03 / 98.22
NPM Average (%) / Sector	-122.49 / -1,697.63
NPM Change Average (%) / Sector	-16.22 / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-47.02 / 185,260.96
ROA Average (%) / Sector	-41.77 / 36,684.70
ROA Change Average (%) / Sector	1.59 / 422,221.66
ROE (%) / Sector	258.21 / 243,762.23 GREAT
ROE Average (%) / Sector	66.61 / 48,758.47 GREAT
ROE Change Average (%) / Sector	-118.87 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

配当

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

登録情報

Analyze Date	2026-08-04 08:02:04
Symbol	RARE
Name	ULTRAGENYX
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	98.49 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	2,453.37 / 9,645.64

ニュース

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 60 Leveroni Court, Novato, CA, United States, 94949

Phone: 415 483 8800

Website: https://www.ultragenyx.com

Employees: 1,371

Sector: Healthcare >> Biotechnology

Description: Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701, an adeno-associated AAV9 gene therapy which is in Phase 2 clinical trial for the treatment of Wilson liver disease. The company has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Regeneron; and Abeona. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.